

# Journal of Visualized Experiments

## Use of a recombinant mosquito densovirus as a gene delivery vector for the functional analysis of genes in mosquito larvae --Manuscript Draft--

<b>Manuscript Number:</b>	JoVE56121R3
<b>Full Title:</b>	Use of a recombinant mosquito densovirus as a gene delivery vector for the functional analysis of genes in mosquito larvae
<b>Article Type:</b>	Invited Methods Article - JoVE Produced Video
<b>Keywords:</b>	Mosquito densovirus, gene delivery vector, small RNA, Aedes albopictus, vector control, artificial intron
<b>Manuscript Classifications:</b>	8.1.158.273: Biology; 8.1.158.273.688: Parasitology
<b>Corresponding Author:</b>	Jinbao Gu Southern Medical University Guangzhou, Guangdong CHINA
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author E-Mail:</b>	daipeng217@126.com
<b>Corresponding Author's Institution:</b>	Southern Medical University
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Liu Pei-Wen
<b>First Author Secondary Information:</b>	
<b>Other Authors:</b>	Liu Pei-Wen
	Xu Jia-Bao
	Dong Yun-Qiao
	Chen Xiao-Guang
<b>Order of Authors Secondary Information:</b>	
<b>Abstract:</b>	
<b>Abstract:</b>	In vivo microinjection is the most commonly used gene transfer technique for analyzing the gene functions in individual mosquitoes. However, this method requires a more technically demanding operation and involves complicated procedures, especially when used in larvae due to their small size, relatively thin and fragile cuticle and high mortality, which limit its application. In contrast, viral vectors for gene delivery have been developed to surmount extracellular and intracellular barriers. These systems have the advantages of easy manipulation, high gene transduction efficiency, long-term maintenance of gene expression, and the ability to produce persistent effects in vivo. Mosquito densoviruses (MDVs) are mosquito-specific, small single-stranded DNA viruses that can effectively deliver foreign nucleic acids into mosquito cells; however, the replacement or insertion of foreign genes to create recombinant viruses typically causes a loss of packaging and/or replication abilities, which is a barrier to the development of these viruses as delivery vectors.
	Herein, we report using an artificial intronic small-RNA expression strategy to develop a non-defective recombinant Aedes aegypti densovirus (AaeDV) in vivo delivery system. Detailed procedures for the construction, packaging, and quantitative analysis of the rAaeDV vectors as well as for larval infection are described.
	This study demonstrates, for the first time, the feasibility of developing a non-defective recombinant MDV miRNA expression system, which providing a powerful tool for the functional analysis of genes in mosquito and establishing a basis for the application of

	viral paratransgenesis for mosquito-borne diseases control. We demonstrated that <i>Aedes albopictus</i> 1st instar larvae could be more easily and effectively infected by introducing the virus into the water body of the larvae breeding site and that the developed rAaeDVs could be used to overexpress or knock down the expression of a specific target gene in larvae, providing a tool for the functional analysis of mosquito genes.
<b>Author Comments:</b>	
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
If this article needs to be "in-press" by a certain date, please indicate the date below and explain in your cover letter.	

**TITLE:**

Use of a Recombinant Mosquito Dengue Virus as a Gene Delivery Vector for the Functional Analysis of Genes in Mosquito Larvae

**AUTHORS & AFFILIATIONS:**

Pei-Wen Liu<sup>1</sup>, Jia-Bao Xu<sup>1</sup>, Yun-Qiao Dong<sup>2</sup>, Xiao-Guang Chen<sup>1</sup>, Jin-Bao Gu<sup>1</sup>

<sup>1</sup>Department of Pathogen Biology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, Guangdong 510515, China

<sup>2</sup>Reproductive Medical Centre of Guangdong Women and Children's Hospital, Guangzhou, Guangdong 511442, China

**E-MAIL ADDRESSES:**

Pei-Wen Liu (irvingliu@163.com)

Jia-Bao Xu (jiabao\_xu@qq.com)

Yun-Qiao Dong (dongyunqiao@126.com)

Xiao-Guang Chen (xgchen2001@hotmail.com)

Jin-Bao Gu (daipeng217@126.com)

**CORRESPONDING AUTHOR:**

Jin-Bao Gu (daipeng217@126.com)

**KEYWORDS:**

Mosquito dengue virus, gene delivery vector, small RNA, *Aedes albopictus*, vector control, artificial intron.

**SHORT ABSTRACT:**

We report using an artificial intronic small RNA expression strategy to develop a non-defective recombinant *Aedes aegypti* dengue virus (AaeDV) *in vivo* delivery system. A detailed procedure for the construction, packaging, and quantitative analysis of the rAaeDV vectors as well as for larval infection is described.

**LONG ABSTRACT:**

*In vivo* microinjection is the most commonly used gene transfer technique for analyzing the gene functions in individual mosquitoes. However, this method requires a more technically demanding operation and involves complicated procedures, especially when used in larvae due to their small size, relatively thin and fragile cuticle, and high mortality, which limit its application. In contrast, viral vectors for gene delivery have been developed to surmount extracellular and intracellular barriers. These systems have the advantages of easy manipulation, high gene transduction efficiency, long-term maintenance of gene expression, and the ability to produce persistent effects *in vivo*. Mosquito dengue viruses (MDVs) are mosquito-specific, small single-stranded DNA viruses that can effectively deliver foreign nucleic acids into mosquito cells; however, the replacement or insertion of foreign genes to create

recombinant viruses typically causes a loss of packaging and/or replication abilities, which is a barrier to the development of these viruses as delivery vectors.

Herein, we report using an artificial intronic small-RNA expression strategy to develop a non-defective recombinant *Aedes aegypti* densovirus (AaeDV) *in vivo* delivery system. Detailed procedures for the construction, packaging and quantitative analysis of the rAaeDV vectors, and for larval infection are described.

This study demonstrates, for the first time, the feasibility of developing a non-defective recombinant MDV micro RNA (miRNA) expression system, and thus providing a powerful tool for the functional analysis of genes in mosquito and establishing a basis for the application of viral paratransgenesis for controlling mosquito-borne diseases. We demonstrated that *Aedes albopictus* 1<sup>st</sup> instar larvae could be easily and effectively infected by introducing the virus into the water body of the larvae breeding site and that the developed rAaeDVs could be used to overexpress or knock down the expression of a specific target gene in larvae, providing a tool for the functional analysis of mosquito genes.

## INTRODUCTION:

Mosquito-borne diseases such as malaria, dengue fever, zika fever and yellow fever, are major international public health problems that continue to account for a significant fraction of the global infectious disease burden<sup>1,2</sup>. Conventional insecticides, which have been used in response to vectors, are a major component of sustainable integrated mosquito control strategy for the prevention of mosquito-borne diseases. However, such strategies have proven to be relatively ineffective or undesirable due to the associated negative environmental impacts as well as the evolution of resistance in mosquito populations<sup>3,4</sup>. For these reasons, there is an urgent need for alternative methods of mosquito control, and the use of transgenic methods to produce sterile male mosquitoes and the release of pathogen-resistant mosquitoes have arisen as promising new control strategies. To develop effective new control methods, such as safe and effective approaches for *in vivo* gene delivery, the comprehensive analysis of mosquito gene function is required.

Direct microinjection of plasmid DNA, double stranded RNA (dsRNA) or small interfering RNA (siRNA) is the most commonly used *in vivo* gene delivery method in mosquitoes. In fact, the production of transgenic strains of mosquitoes still rely on a process of embryo microinjection<sup>5-7</sup>. However, microinjection has several limitations. First, this technique is technically demanding and involves complicated procedures. Second, injection causes a physical insult to the embryo, larvae, pupae and adult, which directly affects the viability of the target organism. Third, it is difficult to immobilize mosquito larvae for microinjection because most live in an aquatic habitat and possess a characteristic wriggling movement. Fourth, the size of 1<sup>st</sup>–2<sup>nd</sup> instar larvae is 10- to 20-fold smaller than that of 4<sup>th</sup> instar and older larvae, and the cuticles of the former are more delicate. These features make it difficult to manipulate 1<sup>st</sup>–2<sup>nd</sup> instar larvae compared to those in older stages. Combined, these factors contribute to a reduced post-injection survival rate for larvae (approximately 5%) compared to adults<sup>8</sup>. Viral-based delivery systems have been developed to overcome the associated extracellular and intracellular barriers. These systems

have the advantages of easy manipulation, high transduction efficiency, long-term and robust levels of expression, and the ability to produce persistent effects *in vivo*. Therefore, gene delivery systems utilizing retroviruses, lentiviruses, and adenoviruses have been widely used in mammalian cell lines and model species. The Sindbis viral expression system had been previously used to analyze the gene function in the adult mosquito; besides the biosafety concerns, however, the injection is still a necessary process for viral infection<sup>9</sup>. Although, the oral delivery by soaking larvae in the dsRNA solution has been reported previously as a feasible delivery method, it is unsuitable for small RNA function analysis<sup>10</sup>. So, effective viral delivery methods must still be developed for mosquitoes.

Mosquito densoviruses (MDVs) are part of the *Densovirinae* subfamily of *Parvoviridae*, and all but one fall within the genus *Brevidensovirus*<sup>11</sup>. MDV virions are non-enveloped and consist of a single-stranded DNA (ssDNA) genome and an icosahedral capsid (20 nm in diameter). The viral genome is approximately 4 kb in size and is replicated within the nuclei of host cells. MDVs are relatively stable in the environment and show a narrow host range with high specificity for mosquitoes. These viruses have the potential to spread and persist naturally in mosquito populations and can invade almost all organs and tissues of these insects, including the midgut, Malpighian tubules, fat body, musculature, neurons, and salivary glands<sup>12</sup>.

Intact MDV genomes can be subcloned into plasmid vectors to produce plasmid-based infectious clones; when these clones are delivered into mosquito cells, the viral genome is extracted from the plasmid vector, and infectious viral particles are produced. Because MDV has a small ssDNA genome, infectious clones are easily constructed and the viral genome can be easily manipulated<sup>11,13</sup>. These characteristics make MDV a valuable agent for examining mosquito biology. However, because nearly all of the viral genome sequence is essential for viral proliferation, the creation of recombinant virus through the replacement or insertion of foreign genes causes a loss in viral packaging and/or replication abilities, which creates a barrier for the development of MDVs as gene delivery vectors. Herein, we report using an artificial intronic small-RNA expression strategy to develop a non-defective rAaeDV *in vivo* RNA delivery system that has the advantages of easy plasmid construction and the maintenance of a functional virus that can produce stable and long-term expression in host cells without the need for wild-type virus. Additionally, this method allows for the easy transduction of larvae.

The protocols for the following steps are described in this study: 1) design of rAaeDVs encoding an intronic small-RNA expression cassette, 2) production of recombinant virus particles using the C6/36 packaging cell line, 3) quantitative analysis of cell-free rAaeDV genome copy numbers, and 4) infection of *Ae. albopictus* larvae by direct introduction of virus into the water body of the larval habitat. Overall, this work demonstrated that specific small RNAs or target genes can be overexpressed or knocked down in mosquito larvae using the developed MDV delivery system.

#### **PROTOCOL:**

All protocols were approved by the Ethical Committee of Southern Medical University

## 1. Designing an Artificial Intron

NOTE: The artificial intron used in this work is 65 bp in length, and the sequence is 5'-GTAAGAGTCGATCGACGCGTTACTAACTGGTACCTCTTCTTTTTTTTTTGATATCCTGCAG-3'.

1.1. Place the *HpaI* restriction site on both ends of artificial intron so that *HpaI* digestion can release the intron from plasmids (see **Figure 1A**).

1.2. Place the two *XbaI* restriction sites in the intron so that *XbaI* digestion can be used to insert small-RNA expression sequences.

1.3. Order the chemical synthesis of full-length DNA sequences of the artificial intron from a DNA manufacturer. The synthetic DNA created is from cloning into a standard pUC19 plasmid.

NOTE: The essential components of the artificial intron include several consensus nucleotide elements, including a 5' donor splice site (DS) with the sequence GUAAGAGU, a conserved branch-point sequence (BPS) with the sequence UACUAAC, a poly-pyrimidine tract (PPT) with the sequence UCUUC(U)<sub>10</sub>, and a 3'-acceptor splice site (AS) with the sequence GAUAUCCUGCAG (**Figure 1A**). Two *XbaI* restriction sites were introduced between the DS and BPS that can be used to insert small-RNA expression sequences. The ability to effectively splice this artificial intron from mammalian and mosquito cells has been previously confirmed<sup>14</sup>.

## 2. Designing an Artificial Intronic Small RNA Expression Cassette

NOTE: For overexpression or knockdown of endogenous miRNA, sequences encoding precursor miRNA or a miRNA sponge were inserted between the DS and BPS. To serve as an example, an endogenous precursor miRNA from *Ae. albopictus* aal-let-7 was selected to construct recombinant viral vectors for miRNA overexpression and knockdown. An anti-let-7 sponge was designed according to previously described methods<sup>15</sup>. To knock down target genes in larvae, we designed specific artificial miRNA (amiRNA) or short hairpin RNA (shRNA) sequences using online software<sup>16,17</sup>; to serve as an example, V-ATPase subunit A mRNA (accession no. AY864912) was selected as a target gene in this study. The amiRNA will be referred to as amiVTP hereafter. All the sequences details of pre-miRNA, sponge, amiRNA and shRNA are described in **Supplemental Table 1**.

2.1. Order the chemical synthesis of full-length cDNA sequences of the precursor miRNAs, miRNA sponges and shRNA with *XbaI* restriction sites on both ends from a DNA manufacturer.

2.2. After receiving the ordered DNA, spin the tubes containing DNA blocks at 10,000–14,000 x g for 1 min to ensure that all dried DNA is at the bottom of the tube.

2.3. Resuspend the dried DNA in DNase-free water to achieve a final concentration of 10 ng/μL.

2.4. Digest the plasmid backbone and cDNA sequences with *XbaI* at 37 °C for 1 h, and then

dephosphorylate the 5' ends of the linearized plasmid backbone with calf intestinal alkaline phosphatase (CIAP) according to the manufacturer's protocol.

2.5. Inactivate CIAP by heating for 60 min at 65 °C.

2.6. Run a 1.0% agarose gel and cut the linearized backbone. Then extract the DNA from the gel slice using a gel extraction kit following the manufacturer's instructions.

2.7. Ligate the DNA fragment into the backbone by T4 DNA ligase (5 U/μL) at 22 °C for 1 h.

2.8. Transform the products of the ligation reaction from step 2.7 into competent *Escherichia coli* (*E. coli*) cells and plate on a Lysogeny Broth (LB) agar plate containing Ampicillin (at a concentration of 100 μg/mL).

2.8.1. Perform the transformation through a heat shock method<sup>18</sup>, and use the appropriate *E. coli* strain. For example, use *E. coli* strain DH5α for heat shock transformation.

2.9. Pick a single colony from step 2.8 and incubate in a culture of 3 mL enriched medium containing Ampicillin (at a concentration of 100 μg/mL).

2.10. Extract the plasmid DNA from the bacterial culture using a mini-prep kit following the manufacturer's instructions. Send the sample to a DNA sequencing company.

**NOTE:** For overexpression or knockdown of endogenous miRNA, the sequences encoding precursor miRNA or a miRNA sponge were inserted between the two *Xba*I sites. All miRNA expression or sponge constructs must be shorter than 400 bp (10% of the viral genome length) due to the packaging limit of the virus<sup>19</sup>.

### **3. Generating a rAaeDV Construct by Cloning a miRNA or shRNA Expression Cassette into a Plasmid Backbone**

**NOTE:** pUCA, an infectious clone consisting of a pUCA plasmid containing the AaeDV genome (3,981 nt)<sup>19</sup>, was kindly provided by Prof. Jonathan Carlson and has been previously described in detail<sup>11</sup>. p7NS1-DsRed expresses a non-structural protein 1 (NS1)-red fluorescent protein (DsRed) fusion protein from the p7 promoter and has been described in detail elsewhere<sup>14</sup>. A human-specific miR-941-1 precursor<sup>20</sup> and its sponge, a scrambled shRNA (CGACGACTATCGTGCAATTTCAAGAG AATTGCACGATAGTCGTCG), were also subcloned into AaeDV as a negative control.

3.1. Ligate the pre-miRNA, sponge, shRNA or an amiVTP expression cassette into the *Hpa*I site of the AaeDV NS1-coding region in the pUCA plasmid backbone as described in the protocol step 2.4 to 2.7.

3.2. Transform the DNA into Stbl3 competent *E. coli* cells and select a positive clone as

described in step 2.8 to 2.10.

3.3. Following this, extract the rAaeDV plasmid from the bacterial cells using a maxi prep kit following the manufacturer's instructions.

**NOTE:** Stbl3 or Stbl4 *E. coli* cells should be utilized for rAaeDV DNA transformation to minimize undesired ITR recombination. A maxi prep should be used to extract the rAaeDV plasmid to obtain a large quantity of DNA (> 100 µg). Before generating the virus, the sequence integrity of the rAaeDV plasmid should always be analyzed by DNA sequencing<sup>21</sup>.

#### 4. Transfecting C6/36 Cells with rAaeDV Plasmids

4.1. Culture C6/36 cells in Roswell Park Memorial Institute (RPMI) 1640 medium containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin in a 28 °C incubator.

4.2. On day 0, plate the cells in ten 25-cm<sup>2</sup> culture flasks 18–20 h before transfection by splitting 90–95% confluent cells in a 1:2 dilution.

**NOTE:** By day 1, the cells should reach 90–95% confluence.

4.3. On day 1, transfect the cells with the series of rAaeDV plasmids<sup>22</sup>.

4.3.1 Dilute 10 µg DNA in 600 µL of RPMI-1640 medium in a microcentrifuge tube and mix gently. Meanwhile, prepare 600 µL of RPMI-1640 medium and 25 µL of transfection reagent per transfection.

4.3.2 Incubate for 5–10 min at room temperature (RT). Then, add 625 µL of the 1640-transfection reagent mixture to the 1640-plasmid DNA mixture.

4.3.3 Incubate this mixture for 20–30 min at RT. Before transfection, wash the cells twice with 2 mL of RPMI-1640 medium.

4.3.4 After the RT incubation (step 4.3.3), add the 1640-transfection reagent DNA plasmid mixture to the 25-cm<sup>2</sup> culture flask and incubate for 6 h at 28 °C.

4.3.5 At approximately 6 h post-transfection, remove the transfection media, wash the cells twice with 5 mL of RPMI-1640 medium, and then add RPMI-1640 medium with 10% FBS.

**NOTE:** rAaeDV shows high rates of infection (95%) in *Ae. albopictus* larvae; however, in our experience, in nearly 50% of infected larvae, the infection was restricted to primary infection sites (*e.g.*, anal papillae and bristle cells) without dissemination<sup>23</sup>. Therefore, if there is a need to infect larvae in multiple tissues, a defective recombinant virus expressing fluorescent protein should be co-infected to enable the visualization of infection sites. For example, to produce defective recombinant virus expressing DsRed, p7NS1-DsRed should be co-transfected with a



helper plasmid into C6/36 cells according to the procedure described above (the cotransfection concentration ratio should be 2:1).

## 5. Harvesting rAaeDV Virions from Transfected C6/36 Cells

5.1. Harvest the cells 5 days after transfection. Dislodge and suspend the cells in the dishes by a 5-mL glass dropper, pipetting up and down with the culture medium. Transfer all cell suspensions to sterile 50-mL tubes.

5.2. Freeze at -80 °C or in a dry ice/ethanol bath for 30 min and then thaw at 37 °C. Vortex for 1 min. Repeat the freeze-and-thaw procedure 3 times.

5.3. Centrifuge the sample at 4,800 x g for 20 min at 4 °C. Collect the supernatant and discard the pellet. Then, pass the supernatant through a 0.22-μm disposable syringe filter. Aliquot and store the final purified virion stocks at -80 °C.

**NOTE:** Avoid repeated freeze-thaw cycles.

## 6. Quantifying rAaeDV

6.1. Prepare the DNA standards. Linearize all rAaeDV plasmids with *HpaI*, and purify the digested products with a gel extraction kit<sup>24</sup>.

6.2. Construct the absolute quantitative standard curve and measure the titer of virus according to previously described methods<sup>25</sup>.

## 7. Mosquito Transduction

7.1. Wash 100 1<sup>st</sup> instar *Ae. albopictus* larvae three times using deionized water, and then, transfer the larvae into a beaker containing 95 mL deionized water. Add 5 mL of the rAaeDV stocks (final concentration of  $1.00 \times 10^{10}$  copies/mL).

7.2. Incubate for 24 h at 28 °C, wash the larvae three times using deionized water, and then transfer the larvae back to the plates and feed regularly.

7.3. Monitor the level of target gene expression in the larvae with qPCR or Western blot (representative results are shown in **Figures 3 and 4**).

**NOTE:** The fluorescence signal detection method can be used to isolate the infected larvae more precisely. For example, to detect fluorescent signals from larvae infected with recombinant virus expressing DsRed, the larvae can be placed on a concavity slide and observed under an inverted fluorescence microscope every 8 h until 2 days post-infection. Once fluorescent larvae are detected, they should be separated into individual plastic test cups to allow for subsequent continuous observation. Larvae with multiple tissues infected can be

identified using this method.

### REPRESENTATIVE RESULTS:

**Strategies for rAaeDV construction.** A defective rAaeDV vector was generated to express the DsRed gene in mosquito larvae. The resulting plasmid contained a NS1-DsRed fusion protein cassette with the VP protein deleted (**Figure 1A**). rAaeDV plasmids containing expression constructs for miRNA, miRNA sponge, shRNA and amiRNA were designed (shown in **Figure 1B**). For example, a rAaeDV vector was generated to overexpress aal-let-7 in mosquito larvae. The resulting plasmid contained an intronic pre-aal-let-7 cassette in the viral NS1 exon (**Figure 1B**). A rAaeDV vector containing an intronic aal-let-7 sponge expression cassette in the viral NS1 exon was generated to knock down aal-let-7 expression in mosquito larvae (**Figure 1B** and **Figure 2B**). A rAaeDV shRNA vector and a rAaeDV amiRNA vector containing intronic shRNA and pre-amiRNA expression cassettes, respectively, were used to knock down V-ATPase mRNA in mosquito larvae (**Figure 2C**).

**Calculating the rAaeDV titers based on a standard curve that generated with the linear regression analysis.** The y-axis represents the Log10 value of standard DNA molecular concentration, and the x-axis indicates the CT value. The CT numbers (x-axis) and Log10 (concentration) values (y-axis) displayed a good correlation ( $R^2 = 0.9988$ ) and meet the equation  $y = -0.288x + 13.87$  (**Figure 3**). Calculate the rAaeDV titers of samples using the linear equation (**Table 1**). Using the method described in the protocol (**step 6.2 and Table 1**), the high titers of rAaeDV (4 mL,  $>7.65 \times 10^{10}$  particles/mL) were harvested. Recombinant viruses (VrepUCA-7, VrepUCA-7s, VrepUCA-amiVTP, VrepUCA-shVTP, VrepUCA941-1, VrepUCA-941-1s, and VrepUCA-shct) were generated by transfecting the corresponding infection clones pUCA-7, pUCA-7s, pUCA-amiVTP, pUCA941-1, pUCA941-1s, pUCA-shct into C6/36 cells (**sections 3, 4 and 5**).

**Determining the miRNA overexpression and knockdown efficiency of rAaeDV vectors.** In the example, 100 1<sup>st</sup> instar larvae were treated with equal amounts ( $1.00 \times 10^{10}$  particles/mL) of rAaeDV containing the intronic pre-let-7 expression vector, the intronic let-7 sponge expression vector, the human-specific pre-miR-941-1 expression vector or the miR-941-1 sponge expression vector by adding the virus into the water body of the larval habitat. Five days after infection, the expression of aal-let-7 was determined by qPCR (**Figure 4**,  $n = 3$ ; **Supplemental Table 2**). The let-7 levels that are displayed as the mean  $\pm$  SD of three biological replicates in the larvae, were substantially increased or decreased by the pre-let-7-expressing rAaeDV (overexpressed by  $2,843.31 \pm 80.72\%$ ,  $p < 0.0001$ , t-test) and the let-7-sponge-expressing rAaeDV (downregulated by  $74.78 \pm 1.60\%$ ,  $p < 0.0001$ , t-test), respectively.

**Monitoring the V-ATPase mRNA knockdown efficiency of rAaeDV vectors.** A total of 100 1<sup>st</sup> instar larvae were treated with equal amounts ( $1.00 \times 10^{10}$  particles/mL) of intronic amiRNA-expressing rAaeDV, intronic shRNA-expressing rAaeDV, human-specific pre-miR-941-1-expressing rAaeDV or scramble shRNA-expressing rAaeDV by adding the virus into the water body of the larval habitat. Five days after infection, the expression of V-ATPase mRNA was determined by qPCR (**Figure 5**,  $n = 3$ ; **Supplemental Table 2**). The V-ATPase level displayed as

the mean  $\pm$  SD of three biological replicates in the larvae was substantially reduced by amiRNA-expressing rAaeDV (downregulated by  $43.01 \pm 6.37\%$ ,  $p = 0.0011$ , t-test) and intronic shRNA-expressing rAaeDV (downregulated by  $72.88 \pm 5.74\%$ ,  $p = 0.0001$ , t-test).

#### FIGURE AND TABLE LEGENDS:

**Figure 1. Schematic organization of the recombinant AaeDV plasmids.** (A) The pNS and pVP viral promoters drive the expression of the NS1/NS2 genes and VP genes, respectively. In the p7NS1-DsRed plasmid, the DsRed gene was fused to the NS1 gene. (B) pUCA-7, pUCA-7s, pUCA-941-1, pUCA-941-1s, pUCA-shct, pUCA-shVTP and pUCA-amiVTP contain artificial introns, including the aal-let-7, aal-let-7 sponge, hsa-miR-941-1, hsa-miR-941-1 sponge, scrambled shRNA, V-ATPase shRNA and artificial miRNA, respectively, which were cloned into the *HpaI* site of the NS1 gene. The artificial intron is shown flanked by a splice donor (DS) and an acceptor site (AS) and contains a branch-point domain (BrP), a poly-pyrimidine tract (PPT) and pre-miRNA. The miRNA sponge or artificial miRNA sequence is inserted inside the intron between the 5-splice site and the BrP.

**Figure 2. Biogenesis of artificial intronic microRNA (miRNA) and strategy for generating miRNA sponges and artificial miRNAs.** (A) Intronic miRNA is co-transcribed within a precursor messenger RNA (pre-mRNA) of NS1, which will be driven by the pNS1 promoter and cleaved out of the pre-mRNA by RNA splicing. Although the exons are ligated to form a mature messenger RNA (mRNA) for NS1 protein synthesis, the spliced intron with the pre-miRNA is further processed into mature miRNA by Dicer. (B) Strategy for generating the anti-let-7 and anti-miR-941-1 constructs. Alignment of anti-let-7 and anti-miR-941-1 sequences with aal-let-7 and hsa-miR-941-1, respectively. Complete matching of the seed regions with the anti-miRNA sequence and tail regions is shown. Both let-7 and miR-941-1 sponges contain three repeat antisense constructs (red letters) that can bind to aal-let-7 and hsa-miR-941-1, respectively. (C) Sequences and predicted precursor structures for the miRNA-based artificial miRNAs and shRNA used in this study. The mature artificial miRNAs and shRNA are shown in red, and their related target mRNA sequences are in blue.

**Figure 3. Standard curve for rAaeDV titration and the calculated concentrations of MDVs.** (A) Real-time qPCR was performed with a pUCA standard that was diluted by 10 times the magnification ratio, and the  $C_T$  value was measured on an ABI 7500 as  $x$ . Copy number was calculated according to step 6.2 and 6.3 with the following formula: copy number ( $y$ ) =  $-0.288x + 10.87$ ;  $R^2 = 0.9988$ .

**Figure 4. Recombinant MDV-mediated aal-let-7 overexpression and knockdown in *Ae. albopictus* larvae.** (A) Analysis of endogenous miRNA expression in larvae after infection with recombinant virus containing the aal-let-7 expression cassette (left panel). (B) The efficiency of the anti-let-7 construct was determined in larvae (right panel). The has-miR-941-1 and has-941-1 sponge (negative control) overexpressed and downregulated the mature let-7 miRNAs, respectively, compared to the basal levels observed in the control group. miRNA abundance was normalized to 5S rRNA, and the data are displayed as the mean  $\pm$  SD of three biological replicates. T-tests were performed at different levels of significance. The asterisks indicate

statistically significant differences between the infected and corresponding mock-treated larvae (four asterisks,  $p < 0.0001$ ).

**Figure 5. Analysis of V-ATPase mRNA expression after infection with recombinant virus containing shRNA and amiRNA cassettes.** mRNA abundance was normalized to aalrpS7. Error bars represent the standard deviation of the  $2^{-\Delta\Delta CT}$  values for V-ATPase mRNA expression in the *Ae. albopictus* larvae as evaluated by real-time RT-PCR (\*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ).

**Table 1. The recombinant MDV  $C_T$  value determined by qPCR corresponds to the x value in the formula, which is used to calculate the y value.** The viral genome copy number in each 1  $\mu$ L sample was obtained by the function power (10, y), which was ultimately multiplied by 40, converting the value to the virus concentration of virus suspension.

**Supplemental Table 1: Sequences of miRNA precursor.**

**Supplemental Table 2: qPCR data.**

## DISCUSSION:

It is important to overcome two of the key barriers that limit rAaeDV construction. The first is the production of defective recombinant virus. It has been reported that MDV can be used as a vector to express appropriately sized foreign genes, such as scorpion insect-specific neurotoxins<sup>20</sup> and the GFP protein; however, regardless of the construction strategy, once the ORFs of MDV are inserted or replaced with exogenous genes, virions cannot form independently unless a helper plasmid is cotransfected to supply the missing indispensable viral proteins. The defective virus is unable to engage in secondary transmission, which occurs *in vivo* in mosquitoes with defective genomes. Our results validate an intronic expression strategy that offers a new paradigm that can overcome the limitations of MDVs with defective genomes to enable the efficient delivery of foreign genes into mosquitoes.

The second is the demanding length limit of the recombinant viral genome imposed by the size of viral capsid. For efficient packaging, the genome size cannot exceed 4,400 nucleotides (110% of the length of the wt MDVs genome). An intronic miRNA expression cassette (including miRNA expression cassette and artificial intron) of no more than 400 nt can be introduced into the AaeDV genome. Although the length of the recombinant virus genome is still suitable for packaging, this delivery system has room for improvement. Because of the limitation in genome length, it is difficult to express genes without defective intronic expression strategies.

It is essential to ensure that C6/36 cells are healthy to enable the successful transfection and packaging of rAaeDV. However, the cationic liposome reagents used here and commercial insect cell specific transfection reagents, do not improve the efficiency of C6/36 cell transfection (40–60%). Therefore, to harvest high-titer recombinant virus, it is necessary to maintain the cells for 5 days after transfection based on previously described growth characteristics<sup>14</sup>. Additionally, for successful larval infection, it is essential for larvae to be in contact with infectious virus particles for 24–36 h to ensure high infection ratios<sup>23</sup>.

In conclusion, the intronic expression strategy described here is the first to overcome the barriers imposed by the generation of defective MDV. This strategy enables the production of non-defective recombinant MDVs that can overexpress or downregulate miRNAs and target genes in mosquitoes. This technique provides a tool for the functional analysis of mosquito genes without the use of complicated larvae microinjection procedures and has clear commercial applications. Further studies will expand the application of the described expression strategy to investigate mosquito biology and paratransgenesis for dengue virus control.

#### **ACKNOWLEDGMENTS:**

The authors acknowledge financial support from the National Key Research and Development Program of China (2016YFC1200500 to Xiao-Guang Chen), the National Natural Science Foundation of China (81672054 and 81371846), the Research Team Programme of the Natural Science Foundation of Guangdong (2014A030312016), and the Scientific and Technological Programme of Guangzhou (201508020263). We gratefully acknowledge Professor Jonathan Carlson (Colorado State University) for kindly providing the pUCA and p7NS1-GFP plasmids and for critically reading this manuscript.

#### **DISCLOSURES:**


The authors declare that they have no competing financial interests.

#### **REFERENCES:**

- 1 Tolle, M. A. Mosquito-borne diseases. *Current problems in pediatric and adolescent health care* **39**, 97-140, doi:10.1016/j.cppeds.2009.01.001 (2009).
- 2 Petersen, L. R., Jamieson, D. J., Powers, A. M. & Honein, M. A. Zika Virus. *The New England journal of medicine* **374**, 1552-1563, doi:10.1056/NEJMra1602113 (2016).
- 3 Roberts, D. R. & Andre, R. G. Insecticide resistance issues in vector-borne disease control. *The American journal of tropical medicine and hygiene* **50**, 21-34 (1994).
- 4 Attaran, A., Roberts, D. R., Curtis, C. F. & Kilama, W. L. Balancing risks on the backs of the poor. *Nature medicine* **6**, 729-731, doi:10.1038/77438 (2000).
- 5 Volohonsky, G. *et al.* Transgenic Expression of the Anti-parasitic Factor TEP1 in the Malaria Mosquito *Anopheles gambiae*. *PLoS pathogens* **13**, e1006113, doi:10.1371/journal.ppat.1006113 (2017).
- 6 Galizi, R. *et al.* A synthetic sex ratio distortion system for the control of the human malaria mosquito. *Nature communications* **5**, 3977, doi:10.1038/ncomms4977 (2014).
- 7 Bourtzis, K., Lees, R. S., Hendrichs, J. & Vreysen, M. J. More than one rabbit out of the hat: Radiation, transgenic and symbiont-based approaches for sustainable management of mosquito and tsetse fly populations. *Acta tropica* **157**, 115-130, doi:10.1016/j.actatropica.2016.01.009 (2016).
- 8 Kumar, S. S. & Puttaraju, H. P. Improvised microinjection technique for mosquito vectors. *The Indian journal of medical research* **136**, 971-978 (2012).
- 9 Attardo, G. M., Higgs, S., Klingler, K. A., Vanlandingham, D. L. & Raikhel, A. S. RNA interference-mediated knockdown of a GATA factor reveals a link to anautogeny in the

- mosquito *Aedes aegypti*. *Proceedings of the National Academy of Sciences of the United States of America* **100**, 13374-13379, doi:10.1073/pnas.2235649100 (2003).
- 10 Singh, A. D., Wong, S., Ryan, C. P. & Whyard, S. Oral delivery of double-stranded RNA in larvae of the yellow fever mosquito, *Aedes aegypti*: implications for pest mosquito control. *Journal of insect science (Online)* **13**, 69, doi:10.1673/031.013.6901 (2013).
- 11 Ward, T. W. *et al.* *Aedes aegypti* transducing densovirus pathogenesis and expression in *Aedes aegypti* and *Anopheles gambiae* larvae. *Insect molecular biology* **10**, 397-405 (2001).
- 12 Carlson, J., Suchman, E. & Buchatsky, L. Densoviruses for control and genetic manipulation of mosquitoes. *Advances in virus research* **68**, 361-392, doi:10.1016/s0065-3527(06)68010-x (2006).
- 13 Barreau, C., Jousset, F. X. & Bergoin, M. Pathogenicity of the *Aedes albopictus* parvovirus (AaPV), a denso-like virus, for *Aedes aegypti* mosquitoes. *Journal of invertebrate pathology* **68**, 299-309, doi:10.1006/jipa.1996.0100 (1996).
- 14 Liu, P. *et al.* Development of non-defective recombinant densovirus vectors for microRNA delivery in the invasive vector mosquito, *Aedes albopictus*. *Scientific reports* **6**, 20979, doi:10.1038/srep20979 (2016).
- 15 Ortega, M. M. & Bouamar, H. Guidelines on Designing MicroRNA Sponges: From Construction to Stable Cell Line. *Methods in molecular biology (Clifton, N.J.)* **1509**, 221-233, doi:10.1007/978-1-4939-6524-3\_20 (2017).
- 16 BLOCK-iT RNAi Designer, <http://rnaidesigner.lifetechnologies.com/rnaiexpress/>
- 17 GE Dharmacon siDesign Center siRNA design tool, [dharmacon.gelifesciences.com/design-center/](http://dharmacon.gelifesciences.com/design-center/)
- 18 Froger, A. & Hall, J. E. Transformation of plasmid DNA into *E. coli* using the heat shock method. *Journal of visualized experiments : JoVE*, 253, doi:10.3791/253 (2007).
- 19 Afanasiev, B. N., Kozlov, Y. V., Carlson, J. O. & Beaty, B. J. Densovirus of *Aedes aegypti* as an expression vector in mosquito cells. *Experimental parasitology* **79**, 322-339, doi:10.1006/expr.1994.1095 (1994).
- 20 Hu, H. Y. *et al.* Evolution of the human-specific microRNA miR-941. *Nature communications* **3**, 1145, doi:10.1038/ncomms2146 (2012).
- 21 Sanger, F., Nicklen, S. & Coulson, A. R. DNA sequencing with chain-terminating inhibitors. *Proceedings of the National Academy of Sciences of the United States of America* **74**, 5463-5467 (1977).
- 22 Dalby, B. *et al.* Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. *Methods (San Diego, Calif.)* **33**, 95-103, doi:10.1016/j.ymeth.2003.11.023 (2004).
- 23 Gu, J. B., Dong, Y. Q., Peng, H. J. & Chen, X. G. A recombinant AeDNA containing the insect-specific toxin, BmK IT1, displayed an increasing pathogenicity on *Aedes albopictus*. *The American journal of tropical medicine and hygiene* **83**, 614-623, doi:10.4269/ajtmh.2010.10-0074 (2010).
- 24 Hou, Y., Zhang, H., Miranda, L. & Lin, S. Serious overestimation in quantitative PCR by circular (supercoiled) plasmid standard: microalgal pcna as the model gene. *PloS one* **5**, e9545, doi:10.1371/journal.pone.0009545 (2010).
- 25 Ding, J. *et al.* Preparation of rAAV9 to Overexpress or Knockdown Genes in Mouse

Hearts. *Journal of visualized experiments : JoVE*, doi:10.3791/54787 (2016).








Figure 3




Figure 4

[Click here to download Figure Figure 4.tif](#)




Figure 5




Table 1. rAaeDV titration calculation

	CT Value Log10 (Concentration)	Concentration	Titer (Particles/mL)
Sample	x	y	2 X Power (10,y)20 X 2 X Power (10,y)
pUCA-941-1	14.97	9.56	7.24E+091.45E+11
pUCA-941-1s	14.73	9.63	8.47E+091.69E+11
pUCA-7	15.93	9.28	3.83E+097.65E+10
pUCA-7s	14.98	9.56	7.20E+091.44E+11
pUCA-shct	15.55	9.39	4.93E+099.87E+10
pUCA-shVTP	15.89	9.29	3.94E+097.88E+10
pUCA-amiVTP	15.16	9.50	6.39E+091.28E+11

;

Name of Material/ Equipment	Company	Catalog Number
Centrifuge machine	Thermo Scientific	75004260
Centrifuge System	Beckman Coulter	363118
GeneJET Gel Extraction Kit	Thermo Scientific	K0691
E.Z.N.A. Plasmid Midi Kit	Omega Biotech	D6904
Purified Agar	OXOID	LP0028A
FastAP Thermosensitive Alkaline Phosphatase (1 U/ $\mu$ L)	Thermo Scientific	EF0651
FastDigest <i>Hpa</i> I	Thermo Scientific	FD1034
FastDigest <i>Xba</i> I	Thermo Scientific	FD0684
T4 DNA Ligase (5 U/ $\mu$ L)	Thermo Scientific	EL0011
TransStbl3 Chemically Competent Cell	Beijing Transgen Biotech	CD521-01
Ampicillin	Beijing Tiangen Biotech	RT501
Roswell Park Memorial Institute (RPMI) 1640 medium	Gibco, Life Technologies	21875109
Fetal Bovine Serum (Australia Origin)	Gibco, Life Technologies	10099141
penicillin/streptomycin	Gibco, Life Technologies	15070063
Lipofectamine 2000 Transfection Reagent	Invitrogen, Life Technologies	11668019
Proteinase K	Promega	MC5008
DNase I (RNase-free)	Invitrogen, Life Technologies	AM2222
SuperReal PreMix Plus (SYBR Green)	Beijing Tiangen Biotech	FP205

**Comments/Description**





1 Alewife Center #200  
Cambridge, MA 02140  
tel. 617.945.9051  
[www.jove.com](http://www.jove.com)

# ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Use of a recombinant mosquito densovirus as a gene delivery vector for the functional analysis of genes in mosquito larvae

Author(s):

Pei-Wen liu<sup>1</sup>, Jia-Bao Xu<sup>1</sup>, Yun-Qiao Dong<sup>2</sup>, Xiao-Guang Chen<sup>1</sup>, Jin-Bao Gu<sup>1\*</sup>

Item 1 (check one box): The Author elects to have the Materials be made available (as described at

<http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

## ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JOVE**” means MyJove Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JOVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JOVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JOVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JOVE agreeing to publish the Article, the Author hereby grants to JOVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JOVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

## ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have



## ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

**11. Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

**12. Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

**13. Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

### CORRESPONDING AUTHOR:

Name:

Jin-Bao Gu

Department:

Department of Pathogen Biology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health

Institution:

Southern Medical University

Article Title:

Use of a recombinant mosquito densovirus as a gene delivery vector for the functional analysis of genes in mosquito larvae

Signature:

*Jinbao Gu*

Date:

2/23/2017

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email [submissions@jove.com](mailto:submissions@jove.com) or call +1.617.945.9051




**Dear Dr. Alisha DSouza**

We appreciate the overall positive reviews of our original manuscript, and we thank the reviewers for their constructive comments and suggestions. We have addressed the points that the reviewers raised as detailed below. I think that by clarifying these points, the paper has been further strengthened. With these revisions, we hope that the paper is now suitable for publication in Journal of Visualized Experiments (JoVE).



**Textual Overlap:** Significant portions of the **Protocol and Representative Results** show significant overlap with previously published work. Please re-write the text indicated in red in the attached document to avoid this overlap.

**Response:** Thank you for your valuable advice. We have rewritten the text of overlap.



[Click here to access/download](#)

**Supplemental File**  
**EDITORIAL CERTIFICATE.pdf**







Click here to access/download  
**Supplemental Code**  
Table S2.xlsx